Sante Ventures
VC Fund
Austin, United States
Sante Ventures is a VC fund in Austin focused on Health Care and Medical. Santé Ventures is a life sciences venture capital firm that invests exclusively in early-stage companies developing innovative new medical technologies or healthcare delivery models. The firm was founded in 2006 and has nearly $1 billion in capital under management.
- Total investments:
- 127
- Last investment:
- Lead investor:
- 61%
- Fund size:
- $330M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Sante Ventures invests in
Stages Sante Ventures invests in
Countries Sante Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 14 contacts → | |||
Round size
- Series A
- $1.8M–$37M
- Series B
- $2.6M–$48M
- Series C
- $5M–$80M
Investment Focus
Industry
- Health Care 50 (39%)
- Medical 29 (23%)
- Biotechnology 25 (20%)
- Therapeutics 17 (13%)
- Medical Device 16 (13%)
Stage
- Series A 51 (40%)
- Series B 20 (16%)
- Series C 14 (11%)
- Series D 6 (5%)
- Seed 5 (4%)
Country
- United States 61 (48%)
- Canada 2 (2%)
- Japan 1 (1%)
- Australia 1 (1%)
- New Zealand 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Jason Brandt
Chief Financial Officer & Chief Compliance Officer
|
Chief Financial Officer & Chief Compliance Officer | Total investments: 1 | Find email | |
|
Auriel August
Principal
|
Principal | Total investments: 1 | Find email | |
Casey Cunningham
Partner & Chief Scientific Officer
|
Partner & Chief Scientific Officer | Total investments: 3 | Find email | |
David Kaufman
Chief Operating Officer
|
Chief Operating Officer | Total investments: 1 | Find email | |
Dennis McWilliams
Managing Director
|
Managing Director | Total investments: 12 | Find email | |
| See all 14 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| ReEmerge is a medical technology company that specializes in cognitive network restoration therapy. | $37M / Series A / Sep 15, 2026 | ||
| RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse™ Cyclic Aspiration System, which includes a novel aspiration pump to allow rapid and consistent removal of blood clots from the brain. RapidPulse is a spinoutof Syntheon LLC., a medical device incubator dedicated to developing innovative products in the medical device industry | $48M / Series B / Jul 16, 2026 | ||
| REVELOHEALTH provides advisory services. Their services include healthcare provider solutions, revenue cycle solutions, price transparency solutions, payment integrity, network claim repricing, data analytics, denial management, and direct-to-employer. | May 27, 2026 | ||
|
SONIRE Therapeutics
|
SONIRE Therapeutics is a clinical-stage medical device company. It is a U.S. subsidiary of SONIRE Therapeutics Co., Ltd.. | $18M / Series A / Apr 15, 2026 | |
| SONIRE Therapeutics Inc. (SONIRE) is working on a next-generation high-intensity focused ultrasound (HIFU) therapy system that will employ acoustic engineering (ultrasound) technologies developed through cutting-edge academic research. SONIRE has been working on a next-generation high-intensity focused ultrasound (HIFU) treatment system as a noveltherapeutic modality with the goal of giving cancer patients and their families a new future. | $18M / Series A / Apr 15, 2026 | ||
| Endovascular Engineering is a medical technology company focused on developing and deploying advanced clot removal solutions for the treatment of venous thromboembolism. It specializes in thrombectomy technologies designed to improve clinical outcomes and procedural efficiency in minimally invasive vascular interventions. The company’s flagshipinnovation is the Hēlo™ Thrombectomy System, a catheter-based device that uses a combination of mechanical agitation and physician-controlled aspiration to remove blood clots. Its technology emphasizes features such as a self-expanding funnel design and dual-action functionality to enhance clot engagement and navigation through complex anatomies. Endovascular Engineering primarily serves healthcare providers, including interventional cardiologists and radiologists, supporting the treatment of conditions such as pulmonary embolism and deep vein thrombosis. | $80M / Series C / Apr 07, 2026 | ||
| Cancer Screening Platform powered by Agentic AI | $4M / Seed / Feb 04, 2026 | ||
| Developer of a solution-focused AI intended to serve health, education and social sectors. | $7.5M / Series A / Feb 03, 2026 | ||
| SONIRE Therapeutics Inc. (SONIRE) is working on a next-generation high-intensity focused ultrasound (HIFU) therapy system that will employ acoustic engineering (ultrasound) technologies developed through cutting-edge academic research. SONIRE has been working on a next-generation high-intensity focused ultrasound (HIFU) treatment system as a noveltherapeutic modality with the goal of giving cancer patients and their families a new future. | $8M / Series C / Jan 23, 2026 | ||
| Brado is an insight-driven brand growth firm. | Venture - Series Unknown / Jan 09, 2026 | ||
| See all 127 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Sante Ventures invest in?
Sante Ventures invests primarily in Health Care, Medical and Biotechnology startups, most often at Series A and Series B stage. Most of the 127 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Sante Ventures's check size?
Sante Ventures typically joins rounds of $1.8M–$37M at Series A, $2.6M–$48M at Series B and $5M–$80M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Sante Ventures participates in.
How do I contact Sante Ventures?
Public channels for Sante Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Sante Ventures?
The team at Sante Ventures includes Jason Brandt (Chief Financial Officer & Chief Compliance Officer), Auriel August (Principal) and Casey Cunningham (Partner & Chief Scientific Officer), among 14 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
